Kyverna’s $319M IPO adds to fervor for autoimmune cell therapies

California biotech Kyverna Therapeutics will garner $319 million from its Thursday morning Nasdaq debut as it rides a small, but welcome, wave of investor enthusiasm for initial public offerings.

The mid-stage cell therapy maker priced at $22 apiece, selling 14.5 million shares Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks